Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266433 | 0.95 | SCN8A (0.65) | SCN8ACYP1A2CYP2D6CYP2C19HRH4 | |
| SCHEMBL10874778 | 0.83 | SCN8A (0.61) | SCN8ANOS1CHRM2DPP7MAOA | |
| SCHEMBL409441 | 0.82 | SCN8A (0.56) | SCN8ACYP1A2CYP2D6CYP2C19HRH3 | |
| SCHEMBL9257479 | 0.82 | CYP1A2 (0.76) | CYP1A2CYP2D6CYP2C19HRH4HRH3 | |
| SCHEMBL15859362 | 0.82 | CYP1A2 (0.76) | CYP1A2CYP2D6CYP2C19HRH4HRH3 | |
| SCHEMBL410123 | 0.80 | SCN8A (0.57) | SCN8ANOS1DPP7MAOA | |
| SCHEMBL16264592 | 0.79 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19HRH4HRH3 | |
| SCHEMBL16264662 | 0.79 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19HRH4HRH3 | |
| SCHEMBL16264624 | 0.79 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19HRH4HRH3 | |
| SCHEMBL921919 | 0.79 | TSHR (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | SCN8A 1959/4885CYP1A2 659/4885CYP2D6 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.